News Article
Trinean Gets Funding
The company announces closing of a 3,5 million Euro funding round.
Trinean, active in the sector of molecular instrumentation, announced the closure of a €3,5 million round of financing. The round was co-lead by new investor Vesalius Biocapital and existing investor Capital-E.
Trinean is a spin off of the University of Ghent (Intec) and the Belgium nanoelectronics research centre IMEC. The company develops and markets the first nanolitre spectrophotometer with corresponding micro fluidic consumables allowing full spectrum UV/VIS spectroscopic measurements in droplets of liquids between 0,5 and 2,5 µL in a micro plate format in a very fast and automated way.
The initial target application is the determination of DNA/RNA concentrations in small sample volumes. This is of great importance to the biotech industry where today valuable DNA/RNA material has to be sacrificed in order to measure these concentrations, and where test procedures are time consuming.
Next to DNA/RNA quantification, other applications will also be targeted such as ADME testing, protein concentration measurements, enzymology, nephelometry and clinical diagnostics. The investment round will allow Trinean to start production, bring its products to the market and develop new applications.
The company is run by a senior management team consisting of Jan Boon (COO), (ex Elscolab, Thermo Life Sciences, Flow Laboratories , Pharmacia Diagnostics) and Prof. Marc Zabeau (CEO) (ex Plant Genetic Systems, Helix, KeyeGene, Genscope, Methexis).
Trinean is a spin off of the University of Ghent (Intec) and the Belgium nanoelectronics research centre IMEC. The company develops and markets the first nanolitre spectrophotometer with corresponding micro fluidic consumables allowing full spectrum UV/VIS spectroscopic measurements in droplets of liquids between 0,5 and 2,5 µL in a micro plate format in a very fast and automated way.
The initial target application is the determination of DNA/RNA concentrations in small sample volumes. This is of great importance to the biotech industry where today valuable DNA/RNA material has to be sacrificed in order to measure these concentrations, and where test procedures are time consuming.
Next to DNA/RNA quantification, other applications will also be targeted such as ADME testing, protein concentration measurements, enzymology, nephelometry and clinical diagnostics. The investment round will allow Trinean to start production, bring its products to the market and develop new applications.
The company is run by a senior management team consisting of Jan Boon (COO), (ex Elscolab, Thermo Life Sciences, Flow Laboratories , Pharmacia Diagnostics) and Prof. Marc Zabeau (CEO) (ex Plant Genetic Systems, Helix, KeyeGene, Genscope, Methexis).
